国产替罗非班治疗不稳定型心绞痛的临床观察

目的观察国产替罗非班在不稳定型心绞痛（UA）药物治疗中的临床效果。方法符合UA的患者284例，根据是否应用替罗非班分为治疗组（160例）和对照组（124例）。观察两组住院期间及出院后共30d内发生的心血管事件（MACE），包括心血管性死亡，新出现的心肌梗死、脑卒中、顽固缺血状态伴ST—T改变，出血并发症及血小板减少情况。结果与对照组（18．8％）相比，治疗组住院期间所观察心血管事件发生率（15．7％）有所降低，P〈0．05。两组严重出血发生率比较差异无统计学意义。治疗组轻度出血比对照组有所增加，但差异无统计学意义（P〉0．05）。结论国产替罗非班在UA治疗中可减少30d内心血管事件，出血事件无明显增加。

Clinical observation on effect of tirofiban in treating patients with unstable angina

Objective To observe the clinical effect and safety of tirofiban in patients with unstable angina. Methods The present study registered 284 UA patients and the patients were divided into the tirofiban group （ n = 160） who received tirofiban and conventional therapy and the control group （ n = 124） who received conventional therapy. The major adverse cardiac （MACE） include refractory ische mia, new myocardial infarction and death, cerebralapoplexy, hemorrhage complication were observed. Resuits The MACE at 30 days was significantly lower in the tirofiban group than in the placebo group （ 15.7% and 18.8% , P 〈 0.05 ）. There was no difference in the incidence of bleeding or platelet decrease between the two groups. Conclusions Tirofiban may further lower the incidence of MACE in treating UA patients on the basis of conventional treatment in the recent 30 days. The rate of hemorrhage com- plications do not increase.